Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 69

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Valproic Acid in Pregnancy Revisited: Neurobehavioral, Biochemical and Molecular Changes Affecting the Embryo and Fetus in Humans and in Animals: A Narrative Review

Ornoy, Asher, Echefu, Boniface, Becker, Maria · 2023 · International Journal of Molecular Sciences

Abstract

Valproic acid (VPA) is a very effective anticonvulsant and mood stabilizer with relatively few side effects. Being an epigenetic modulator, it undergoes clinical trials for the treatment of advanced prostatic and breast cancer. However, in pregnancy, it seems to be the most teratogenic antiepileptic drug. Among the proven effects are congenital malformations in about 10%. The more common congenital malformations are neural tube defects, cardiac anomalies, urogenital malformations including hypospadias, skeletal malformations and orofacial clefts. These effects are dose related; daily doses below 600 mg have a limited teratogenic potential. VPA, when added to other anti-seizure medications, increases the malformations rate. It induces malformations even when taken for indications other than epilepsy, adding to the data that epilepsy is not responsible for the teratogenic effects. VPA increases the rate of neurodevelopmental problems causing reduced cognitive abilities and language impairment. It also increases the prevalence of specific neurodevelopmental syndromes like autism (ASD) and Attention Deficit Hyperactivity Disorder (ADHD). High doses of folic acid administered prior to and during pregnancy might alleviate some of the teratogenic effect of VPA and other AEDs. Several teratogenic mechanisms are proposed for VPA, but the most important mechanisms seem to be its effects on the metabolism of folate, SAMe and histones, thus affecting DNA methylation. VPA crosses the human placenta and was found at higher concentrations in fetal blood. Its concentrations in milk are low, therefore nursing is permitted. Animal studies generally recapitulate human data.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms25010390

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Research works printed but not linked: 230

  1. Ornoy, 2003, The impact of intrauterine exposure versus postnatal environment in neurodevelopmental toxicity: Long-term neurobehavioral studies in children at risk for developmental disorders, Toxicol. Lett., 140–141, 171, 10.1016/S0378-4274(02)00505-2 · DOI
  2. Arnon, 2000, The use of psychiatric drugs in pregnancy and lactation, Isr. J. Psychiatry Relat. Sci., 37, 205
  3. Jentink, 2010, Valproic acid monotherapy in pregnancy and major congenital malformations, New Engl. J. Med., 362, 2185, 10.1056/NEJMoa0907328 · DOI · Paper page
  4. Ornoy, 2006, Neuroteratogens in man: An overview with special emphasis on the teratogenicity of antiepileptic drugs in pregnancy, Reprod. Toxicol., 22, 214, 10.1016/j.reprotox.2006.03.014 · DOI
  5. Kultima, 2004, Valproic Acid Teratogenicity: A Toxicogenomics Approach, Environ. Health Perspect., 112, 1225, 10.1289/txg.7034 · DOI
  6. Shechtman, 2008, Pregnancy outcome after in utero exposure to valproate: Evidence of dose relationship in teratogenic effect, CNS Drugs, 22, 325, 10.2165/00023210-200822040-00004 · DOI
  7. Morrow, 2006, Malformation risks of antiepileptic drugs in pregnancy: A prospective study from the UK Epilepsy and Pregnancy Register, J. Neurol. Neurosurg. Psychiatry, 77, 193, 10.1136/jnnp.2005.074203 · DOI · Paper page
  8. Bromley, 2014, Treatment for epilepsy in pregnancy: Neurodevelopmental outcomes in the child, Cochrane Database Syst. Rev., 10, CD010236
  9. Weston, 2016, Monotherapy treatment of epilepsy in pregnancy: Congenital malformation outcomes in the child, Cochrane Database Syst. Rev., 11, CD010224
  10. Kini, 2006, Dysmorphic features: An important clue to the diagnosis and severity of fetal anticonvulsant syndromes, Arch. Dis. Child. Fetal Neonatal Ed., 91, F90, 10.1136/adc.2004.067421 · DOI
  11. Fried, 2004, Malformation rates in children of women with untreated epilepsy: A meta-analysis, Drug Saf., 27, 197, 10.2165/00002018-200427030-00004 · DOI · Paper page
  12. Anmella, 2019, Expert advice on the management of valproate in women with bipolar disorder at childbearing age, Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol., 29, 1199, 10.1016/j.euroneuro.2019.09.007 · DOI
  13. Speidel, 1972, Maternal epilepsy and abnormalities of the fetus and newborn, Lancet, 2, 839, 10.1016/S0140-6736(72)92209-X · DOI · Paper page
  14. Bjerkedal, 1973, The course and outcome of pregnancy in women with epilepsy, Acta Obs. Gynecol. Scand., 52, 245, 10.3109/00016347309158321 · DOI
  15. Shapiro, 1976, Anticonvulsants and parental epilepsy in the development of birth defects, Lancet, 1, 272, 10.1016/S0140-6736(76)91403-3 · DOI · Paper page
  16. DiLiberti, 1984, The fetal valproate syndrome, Am. J. Med. Genet., 19, 473, 10.1002/ajmg.1320190308 · DOI · Paper page
  17. Kozma, 2001, Valproic acid embryopathy: Report of two siblings with further expansion of the phenotypic abnormalities and a review of the literature, Am. J. Med. Genet., 98, 168, 10.1002/1096-8628(20010115)98:2<168::AID-AJMG1026>3.0.CO;2-O · DOI
  18. Bulut, 2017, Fetal Valproate Syndrome, Pediatr. Neonatol., 58, 158, 10.1016/j.pedneo.2016.01.009 · DOI
  19. Bromley, 2019, Diagnosis and management of individuals with Fetal Valproate Spectrum Disorder; a consensus statement from the European Reference Network for Congenital Malformations and Intellectual Disability, Orphanet J. Rare Dis., 14, 180, 10.1186/s13023-019-1064-y · DOI
  20. Ardinger, 1988, Verification of the fetal valproate syndrome phenotype, Am. J. Med. Genet., 29, 171, 10.1002/ajmg.1320290123 · DOI · Paper page
  21. Bromley, 2019, Intellectual functioning in clinically confirmed fetal valproate syndrome, Neurotoxicol. Teratol., 71, 16, 10.1016/j.ntt.2018.11.003 · DOI
  22. Bromley, 2023, Monotherapy treatment of epilepsy in pregnancy: Congenital malformation outcomes in the child, Cochrane Database Syst. Rev., 8, CD010224
  23. Rihtman, 2013, Developmental outcomes at preschool age after fetal exposure to valproic acid and lamotrigine: Cognitive, motor, sensory and behavioral function, Reprod. Toxicol., 41, 115, 10.1016/j.reprotox.2013.06.001 · DOI
  24. Cohen, 2019, Fetal antiepileptic drug exposure and learning and memory functioning at 6 years of age: The NEAD prospective observational study, Epilepsy Behav., 92, 154, 10.1016/j.yebeh.2018.12.031 · DOI
  25. Ornoy, A., Becker, M., Weinstein-Fudim, L., and Ergaz, Z. (2020). S-Adenosine Methionine (SAMe) and Valproic Acid (VPA) as Epigenetic Modulators: Special Emphasis on their Interactions Affecting Nervous Tissue during Pregnancy. Int. J. Mol. Sci., 21. · DOI · Paper page
  26. Singh, D., Gupta, S., Verma, I., Morsy, M.A., Nair, A.B., and Ahmed, A.F. (2021). Hidden pharmacological activities of valproic acid: A new insight. Biomed. Pharmacother., 142. · DOI
  27. Verloes, 1990, Proximal phocomelia and radial ray aplasia in fetal valproic syndrome, Eur. J. Pediatr., 149, 266, 10.1007/BF02106290 · DOI
  28. Bromfield, 2008, Valproate teratogenicity and epilepsy syndrome, Epilepsia, 49, 2122, 10.1111/j.1528-1167.2008.01696.x · DOI
  29. Tanoshima, 2015, Risks of congenital malformations in offspring exposed to valproic acid in utero: A systematic review and cumulative meta-analysis, Clin. Pharmacol. Ther., 98, 417, 10.1002/cpt.158 · DOI
  30. Eadie, 2005, Should valproate be taken during pregnancy?, Ther. Clin. Risk Manag., 1, 21, 10.2147/tcrm.1.1.21.53605 · DOI
  31. Campbell, 2014, Malformation risks of antiepileptic drug monotherapies in pregnancy: Updated results from the UK and Ireland Epilepsy and Pregnancy Registers, J. Neurol. Neurosurg. Psychiatry, 85, 1029, 10.1136/jnnp-2013-306318 · DOI · Paper page
  32. Artama, 2005, Antiepileptic drug use of women with epilepsy and congenital malformations in offspring, Neurology, 64, 1874, 10.1212/01.WNL.0000163771.96962.1F · DOI · Paper page
  33. Smith, 2012, Comparative safety of antiepileptic drugs during pregnancy, Neurology, 78, 1692, 10.1212/WNL.0b013e3182574f39 · DOI · Paper page
  34. Vajda, 2007, The Australian Register of Antiepileptic Drugs in Pregnancy: The first 1002 pregnancies, Aust. N. Z. J. Obstet. Gynaecol., 47, 468, 10.1111/j.1479-828X.2007.00781.x · DOI
  35. Ornoy, 1993, Clinical teratology, West. J. Med., 159, 382
  36. Philbrook, 2019, Characterizing the effects of in utero exposure to valproic acid on murine fetal heart development, Birth Defects Res., 111, 1551, 10.1002/bdr2.1610 · DOI
  37. Yerby, 1994, Pregnancy, teratogenesis, and epilepsy, Neurol. Clin., 12, 749, 10.1016/S0733-8619(18)30075-6 · DOI
  38. Bjerkedal, 1982, Valproic acid and spina bifida, Lancet, 2, 1096, 10.1016/S0140-6736(82)90018-6 · DOI · Paper page
  39. Kim, 1994, Developmental abnormalities of the female reproductive tract, Curr. Opin. Obstet. Gynecol., 6, 518, 10.1097/00001703-199412000-00009 · doi:10.1097/00001703-199412000-00009
  40. Okada, 2004, Amidic modification of valproic acid reduces skeletal teratogenicity in mice, Birth Defects Res. Part B Dev. Reprod. Toxicol., 71, 47, 10.1002/bdrb.10057 · doi:10.1002/bdrb.10057
  41. Yerby, 2003, Management issues for women with epilepsy: Neural tube defects and folic acid supplementation, Neurology, 61, S23, 10.1212/WNL.61.6_suppl_2.S23 · DOI
  42. Koren, 2006, Major malformations with valproic acid, Can. Fam. Physician Med. Fam. Can., 52, 441
  43. Perucca, 2006, Prenatal exposure to antiepileptic drugs, Lancet, 367, 1467, 10.1016/S0140-6736(06)68627-3 · DOI
  44. Malm, 2002, Valproate embryopathy in three sets of siblings: Further proof of hereditary susceptibility, Neurology, 59, 630, 10.1212/WNL.59.4.630 · DOI
  45. Alsdorf, 2005, Teratogenicity of sodium valproate, Expert. Opin. Drug Saf., 4, 345, 10.1517/14740338.4.2.345 · DOI · Paper page
  46. 2008, Risk of hypospadias in newborn infants exposed to valproic acid during the first trimester of pregnancy: A case-control study in Spain, Drug Saf., 31, 537, 10.2165/00002018-200831060-00008 · DOI
  47. Dalens, 1980, Bronchopulmonary dysplasia following negative pressure ventilation, J. Pediatr., 97, 332, 10.1016/S0022-3476(80)80517-8 · DOI
  48. Gomez, 1981, Possible teratogenicity of valproic acid, J. Pediatr., 98, 508, 10.1016/S0022-3476(81)80743-3 · DOI
  49. Lindhout, 1992, Spectrum of neural-tube defects in 34 infants prenatally exposed to antiepileptic drugs, Neurology, 42, 111
  50. Robert, 1983, Is valproic acid teratogenic?, Rev. Neurol., 139, 445
  51. Kaneko, 1999, Congenital malformations due to antiepileptic drugs, Epilepsy Res., 33, 145, 10.1016/S0920-1211(98)00084-9 · DOI · Paper page
  52. Matalon, 2002, The teratogenic effect of carbamazepine: A meta-analysis of 1255 exposures, Reprod. Toxicol., 16, 9, 10.1016/S0890-6238(01)00199-X · DOI · Paper page
  53. Laegreid, 1993, Benzodiazepine amplification of valproate teratogenic effects in children of mothers with absence epilepsy, Neuropediatrics, 24, 88, 10.1055/s-2008-1071520 · DOI
  54. Holmes, 2011, Fetal effects of anticonvulsant polytherapies: Different risks from different drug combinations, Arch Neurol., 68, 1275, 10.1001/archneurol.2011.133 · DOI · Paper page
  55. Tomson, 2015, Valproate in the treatment of epilepsy in girls and women of childbearing potential, Epilepsia, 56, 1006, 10.1111/epi.13021 · DOI · Paper page
  56. Zaccara, 2014, Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs, Epileptic Disord. Int. Epilepsy J. Videotape, 16, 409, 10.1684/epd.2014.0714 · DOI · Paper page
  57. Mawer, 2002, Outcome of pregnancy in women attending an outpatient epilepsy clinic: Adverse features associated with higher doses of sodium valproate, Seizure, 11, 512, 10.1016/S1059-1311(02)00135-8 · DOI
  58. Winter, 1987, Fetal valproate syndrome: Is there a recognisable phenotype?, J. Med. Genet., 24, 692, 10.1136/jmg.24.11.692 · DOI
  59. Dean, 2000, Developing diagnostic criteria for the fetal anticonvulsant syndromes, Seizure, 9, 233, 10.1053/seiz.2000.0392 · DOI
  60. Koch, 1996, Antiepileptic drug treatment in pregnancy: Drug side effect in the neonate and neurological outcome, Acta Paediatr. Int. J. Paediatr., 85, 739, 10.1111/j.1651-2227.1996.tb14137.x · DOI
  61. Nicolai, 2008, Neurodevelopmental delay in children exposed to antiepileptic drugs in utero: A critical review directed at structural study-bias, J. Neurol. Sci., 271, 1, 10.1016/j.jns.2008.03.004 · DOI
  62. Christianson, 1994, Fetal Valproate Syndrome: Clinical and Neuro-developmental Features in Two Sibling Pairs, Dev. Med. Child Neurol., 36, 361, 10.1111/j.1469-8749.1994.tb11858.x · DOI · Paper page
  63. Dean, 2002, Long term health and neurodevelopment in children exposed to antiepileptic drugs before birth, J. Med. Genet., 39, 251, 10.1136/jmg.39.4.251 · DOI · Paper page
  64. Viinikainen, 2006, The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children, Epilepsy Behav., 9, 636, 10.1016/j.yebeh.2006.08.007 · DOI
  65. Adab, 2001, Additional educational needs in children born to mothers with epilepsy, J. Neurol. Neurosurg. Psychiatry, 70, 15, 10.1136/jnnp.70.1.15 · DOI · Paper page
  66. Adab, 2004, The longer term outcome of children born to mothers with epilepsy, J. Neurol. Neurosurg. Psychiatry, 75, 1575, 10.1136/jnnp.2003.029132 · DOI · Paper page
  67. Langer, 1994, Isolated fetal bilateral radial ray reduction associated with valproic acid usage, Fetal Diagn. Ther., 9, 155, 10.1159/000263924 · DOI
  68. Gaily, 2004, Normal intelligence in children with prenatal exposure to carbamazepine, Neurology, 62, 28, 10.1212/WNL.62.1.28 · DOI · Paper page
  69. Eriksson, 2005, Children exposed to valproate in utero—population based evaluation of risks and confounding factors for long-term neurocognitive development, Epilepsy Res., 65, 189, 10.1016/j.eplepsyres.2005.06.001 · DOI
  70. Daugaard, 2020, Association of Prenatal Exposure to Valproate and Other Antiepileptic Drugs with Intellectual Disability and Delayed Childhood Milestones, JAMA Netw. Open, 3, e2025570, 10.1001/jamanetworkopen.2020.25570 · DOI
  71. Tomson, 2019, Management of epilepsy in pregnancy: A report from the International League Against Epilepsy Task Force on Women and Pregnancy, Epileptic Disord., 21, 497, 10.1684/epd.2019.1105 · DOI · Paper page
  72. Wiggs, 2020, Antiseizure medication use during pregnancy and risk of ASD and ADHD in children, Neurology, 95, e3232, 10.1212/WNL.0000000000010993 · DOI
  73. Williams, 1997, A male with fetal valproate syndrome and autism, Dev. Med. Child Neurol., 39, 632, 10.1111/j.1469-8749.1997.tb07500.x · DOI · Paper page
  74. Bromley, 2013, The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs, J. Neurol. Neurosurg. Psychiatry, 84, 637, 10.1136/jnnp-2012-304270 · DOI · Paper page
  75. Wood, 2015, Prospective assessment of autism traits in children exposed to antiepileptic drugs during pregnancy, Epilepsia, 56, 1047, 10.1111/epi.13007 · DOI
  76. Honybun, 2021, Prenatal valproate exposure and adverse neurodevelopmental outcomes: Does sex matter?, Epilepsia, 62, 709, 10.1111/epi.16827 · DOI
  77. Petersen, 2016, Risks and benefits of psychotropic medication in pregnancy: Cohort studies based on UK electronic primary care health records, Health Technol. Assess., 20, 1, 10.3310/hta20230 · DOI
  78. Pittschieler, 2008, Spontaneous abortion and the prophylactic effect of folic acid supplementation in epileptic women undergoing antiepileptic therapy, J. Neurol., 255, 1926, 10.1007/s00415-008-0029-1 · DOI
  79. Błaszczyk, B., Miziak, B., Pluta, R., and Czuczwar, S.J. (2022). Epilepsy in Pregnancy-Management Principles and Focus on Valproate. Int. J. Mol. Sci., 23. · DOI
  80. Baxter, 2014, Valproate and folic acid in pregnancy: Associations with autism, Dev. Med. Child Neurol., 56, 604, 10.1111/dmcn.12498 · DOI
  81. Janz, D., Bossi, L., Dam, M., Helge, H., Richens, A., and Schmidt, D. (1982). Epilepsy, Pregnancy, and the Child, Raven Press.
  82. Albani, 1984, Differential transplacental binding of valproic acid: Influence of free fatty acids, Br. J. Clin. Pharmacol., 17, 759, 10.1111/j.1365-2125.1984.tb02414.x · DOI
  83. Kacirova, 2015, Serum levels of valproic acid during delivery in mothers and in umbilical cord—Correlation with birth length and weight, Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czechoslov., 159, 569, 10.5507/bp.2015.055 · DOI
  84. Kacirova, I., Grundmann, M., and Brozmanova, H. (2021). Valproic Acid Concentrations in Mothers, Colostrum and Breastfed Infants during the Early Postpartum Period: Comparison with Concentrations Determined during Delivery and in the Mature Milk Period. Pharmaceutics, 13. · DOI
  85. Froescher, 1984, Valproic acid in breast milk: How much is really there?, Ther. Drug Monit., 6, 272, 10.1097/00007691-198409000-00003 · DOI
  86. Bennet, P.N. (1988). Drugs and Human Lactation, Elsevier.
  87. Swanson, 1978, Excretion of valproic acid into semen of rabbits and man, Epilepsia, 19, 541, 10.1111/j.1528-1157.1978.tb05034.x · DOI
  88. Yerby, 1999, Male infertility: Possible association with valproate exposure, Epilepsia, 40, 520, 10.1111/j.1528-1157.1999.tb00752.x · DOI
  89. Kaaja, 2003, Major malformations in offspring of women with epilepsy, Neurology, 60, 575, 10.1212/01.WNL.0000044157.28073.DC · DOI · Paper page
  90. Janz, 1994, Are antiepileptic drugs harmful when taken during pregnancy?, J. Perinat. Med., 22, 367
  91. Bold, 2018, Spinal nerve defects in mouse embryos prenatally exposed to valproic acid, Anat. Sci. Int., 93, 35, 10.1007/s12565-016-0363-9 · DOI
  92. Giavini, 2013, Methionine pretreatment enhances the effects of valproate on axial development in a cd1 mouse model, Birth Defects Res. Part B-Dev. Reprod. Toxicol., 98, 328, 10.1002/bdrb.21069 · DOI
  93. Shafique, 2021, Gestational valproic acid exposure induces epigenetic modifications in murine decidua, Placenta, 107, 31, 10.1016/j.placenta.2021.03.004 · DOI
  94. Tiboni, 2015, Prevention of valproic acid-induced neural tube defects by sildenafil citrate, Reprod. Toxicol., 56, 175, 10.1016/j.reprotox.2015.03.004 · DOI
  95. Elphick, 2012, Conserved valproic-acid-induced lipid droplet formation in Dictyostelium and human hepatocytes identifies structurally active compounds, Dis. Models Mech., 5, 231, 10.1242/dmm.008391 · doi:10.1242/dmm.008391
  96. Goetzl, L. (2012). Queenan’s Management of High-Risk Pregnancy: An Evidence-Based Approach, Wiley-Blackwell.
  97. Salimi, 2022, Selenium and L-carnitine protects from valproic acid-Induced oxidative stress and mitochondrial damages in rat cortical neurons, Drug Chem. Toxicol., 45, 1150, 10.1080/01480545.2020.1810259 · DOI
  98. Shafique, 2020, Role of Cbp, p300 and Akt in valproic acid induced neural tube defects in CD-1 mouse embryos, Reprod. Toxicol., 95, 86, 10.1016/j.reprotox.2020.05.008 · DOI
  99. Takla, T.N., Luo, J., Sudyk, R., Huang, J., Walker, J.C., Vora, N.L., Sexton, J.Z., Parent, J.M., and Tidball, A.M. (2023). A Shared Pathogenic Mechanism for Valproic Acid and SHROOM3 Knockout in a Brain Organoid Model of Neural Tube Defects. Cells, 12. · doi:10.1101/2023.04.11.536245
  100. Tiboni, 2021, Valproic acid alters nitric oxide status in neurulating mouse embryos, Reprod. Toxicol., 99, 152, 10.1016/j.reprotox.2020.08.012 · DOI
  101. Wachholz, 2021, From the Farm to the Lab: How Chicken Embryos Contribute to the Field of Teratology, Front. Genet., 12, 666726, 10.3389/fgene.2021.666726 · DOI
  102. Binkerd, 1988, Evaluation of valproic acid (VPA) developmental toxicity and pharmacokinetics in Sprague-Dawley rats, Fundam. Appl. Toxicol. Off. J. Soc. Toxicol., 11, 485, 10.1093/toxsci/11.1.485 · doi:10.1093/toxsci/11.1.485
  103. Lin, 2019, Teratogenicity of valproic acid and its constitutional isomer, amide derivative valnoctamide in mice, Birth Defects Res., 111, 1013, 10.1002/bdr2.1406 · DOI
  104. Hendrickx, 1988, Valproic acid developmental toxicity and pharmacokinetics in the rhesus monkey: An interspecies comparison, Teratology, 38, 329, 10.1002/tera.1420380405 · DOI
  105. Jazayeri, 2020, A rat model of valproate teratogenicity from chronic oral treatment during pregnancy, Epilepsia, 61, 1291, 10.1111/epi.16536 · DOI
  106. Menegola, 1996, Teratogenic effects of sodium valproate in mice and rats at midgestation and at term, Teratog. Carcinog. Mutagen., 16, 97, 10.1002/(SICI)1520-6866(1996)16:2<97::AID-TCM4>3.0.CO;2-A · DOI
  107. Ornoy, 2019, S-adenosyl methionine prevents ASD like behaviors triggered by early postnatal valproic acid exposure in very young mice, Neurotoxicol. Teratol., 71, 64, 10.1016/j.ntt.2018.01.005 · DOI · Paper page
  108. Broccia, 2010, VPA-related axial skeletal defects and apoptosis: A proposed event cascade, Reprod. Toxicol., 29, 106, 10.1016/j.reprotox.2009.10.004 · DOI
  109. Elmazar, 1993, Trimethoprim potentiates valproic acid-induced Neural Tube Defects (NTDs) in mice, Reprod. Toxicol., 7, 249, 10.1016/0890-6238(93)90231-U · DOI
  110. Banji, 2011, Amelioration of behavioral aberrations and oxidative markers by green tea extract in valproate induced autism in animals, Brain Res., 1410, 141, 10.1016/j.brainres.2011.06.063 · DOI
  111. Nau, 2011, Potency ranking of valproic acid analogues as to inhibition of cardiac differentiation of embryonic stem cells in comparison to their in vivo embryotoxicity, Reprod. Toxicol., 31, 375, 10.1016/j.reprotox.2010.11.012 · DOI
  112. Michaelis, 2004, Valproic Acid Inhibits Angiogenesis in Vitro and in Vivo, Mol. Pharmacol., 65, 520, 10.1124/mol.65.3.520 · DOI · Paper page
  113. Nau, 1991, Valproic Acid-Induced Neural Tube Defects in Mouse and Human: Aspects of Chirality, Alternative Drug Development, Pharmacokinetics and Possible Mechanisms, Pharmacol. Toxicol., 69, 310, 10.1111/j.1600-0773.1991.tb01303.x · DOI · Paper page
  114. Wang, 2010, Selective neuronal vulnerability to oxidative stress in the brain, Front. Aging Neurosci., 2, 12
  115. Wegner, 1991, Diurnal variation of folate concentrations in mouse embryo and plasma: The protective effect of folinic acid on valproic-acid-induced teratogenicity is time dependent, Reprod. Toxicol., 5, 465, 10.1016/0890-6238(91)90017-A · DOI
  116. Hara, 2012, Effect of prenatal valproic acid exposure on cortical morphology in female mice, J. Pharmacol. Sci., 118, 543, 10.1254/jphs.12025SC · DOI
  117. Sawada, K., Kamiya, S., and Aoki, I. (2021). Neonatal valproic acid exposure produces altered gyrification related to increased parvalbumin-immunopositive neuron density with thickened sulcal floors. PLoS ONE, 16. · DOI
  118. Fueta, 2018, Prenatal exposure to valproic acid alters the development of excitability in the postnatal rat hippocampus, NeuroToxicology, 65, 1, 10.1016/j.neuro.2018.01.001 · DOI
  119. Ezhilarasan, 2022, Valproic acid induced liver injury: An insight into molecular toxicological mechanism, Environ. Toxicol. Pharmacol., 95, 103967, 10.1016/j.etap.2022.103967 · DOI
  120. Shakya, 2016, Hepatotoxicity of Valproate on Fetal Mice Liver, IJSR-Int. J. Sci. Res. Med. Sci., 5, 79
  121. Akta, 2010, The effects of valproic acid on renal corpuscle of pregnant rats and protective role of folic acid and vitamin E, Afr. J. Biotechnol., 9, 5605
  122. Raza, 2000, Pathomorphological changes in mouse liver and kidney during prolonged valproate administration, Int. J. Tissue React., 22, 15
  123. Wu, G., Nan, C., Rollo, J.C., Huang, X., and Tian, J. (2010). Sodium valproate-induced congenital cardiac abnormalities in mice are associated with the inhibition of histone deacetylase. J. Biomed. Sci., 17. · DOI
  124. Avagliano, 2019, Overview on Neural tube defects: From development to physical characteristics, Birth Defects Res., 111, 1455, 10.1002/bdr2.1380 · DOI · Paper page
  125. Genton, 2006, Valproic acid in epilepsy: Pregnancy-related issues, Drug Saf., 29, 1, 10.2165/00002018-200629010-00001 · DOI
  126. Hansen, 2021, Valproic acid promotes SOD2 acetylation: A potential mechanism of valproic acid-induced oxidative stress in developing systems Valproic acid promotes SOD2 acetylation: A potential mechanism of valproic acid-induced oxidative stress in developing systems Valproic acid promotes SOD2 acetylation: A potential mechanism of valproic acid-induced oxidative stress in developing systems, Free Radic. Res., 55, 1130, 10.1080/10715762.2021.2017913 · DOI
  127. Lundberg, 2004, Mapping a chromosomal locus for valproic acid-induced exencephaly in mice, Mamm. Genome, 15, 361, 10.1007/s00335-004-2345-9 · doi:10.1007/s00335-004-2345-9
  128. Menegola, 2005, Inhibition of histone deacetylase activity on specific embryonic tissues as a new mechanism for teratogenicity, Birth Defects Res. Part B Dev. Reprod. Toxicol., 74, 392, 10.1002/bdrb.20053 · DOI
  129. Ehlers, 1996, Methionine Reduces the Valproic Acid-Induced Spina Bifida Rate in Mice without Altering Valproic Acid Kinetics, J. Nutr., 126, 67, 10.1093/jn/126.1.67 · DOI
  130. Arshaduddin, 2000, Vitamin E decreases valproic acid induced neural tube defects in mice, Neurosci. Lett., 292, 179, 10.1016/S0304-3940(00)01457-9 · DOI
  131. Chaliha, 2020, A Systematic Review of the Valproic-Acid-Induced Rodent Model of Autism, Dev. Neurosci., 42, 12, 10.1159/000509109 · DOI · Paper page
  132. Wagner, 2006, A new neurobehavioral model of autism in mice: Pre- and postnatal exposure to sodium valproate, J. Autism Dev. Disord., 36, 779, 10.1007/s10803-006-0117-y · DOI · Paper page
  133. Arndt, 2005, The teratology of autism, Int. J. Dev. Neurosci., 23, 189, 10.1016/j.ijdevneu.2004.11.001 · DOI · Paper page
  134. Fereshetyan, 2021, Assessment of behavioral, morphological and electrophysiological changes in prenatal and postnatal valproate induced rat models of autism spectrum disorder, Sci. Rep., 11, 23471, 10.1038/s41598-021-02994-6 · DOI
  135. Schneider, 2008, Gender-specific behavioral and immunological alterations in an animal model of autism induced by prenatal exposure to valproic acid, Psychoneuroendocrinology, 33, 728, 10.1016/j.psyneuen.2008.02.011 · DOI · Paper page
  136. Nway, 2018, Social behavior, neuroimmune markers and glutamic acid decarboxylase levels in a rat model of valproic acid-induced autism, J. Toxicol. Sci., 43, 631, 10.2131/jts.43.631 · DOI
  137. Kawada, 2018, Involvement of endoplasmic reticulum stress and neurite outgrowth in the model mice of autism spectrum disorder, Neurochem. Int., 119, 115, 10.1016/j.neuint.2017.07.004 · DOI
  138. Diniz, 2021, BALB/c female subjected to valproic acid during gestational period exhibited greater microglial and behavioral changes than male mice: A significant contra intuitive result, Int. J. Dev. Neurosci., 81, 37, 10.1002/jdn.10072 · DOI
  139. Legato, M.J., Feldberg, D., and Glezerman, M. (2023). Sex, Gender, and Epigenetics: From Molecule to Bedside, Academic Press.
  140. Ornoy, A., Gorobets, D., Weinstein-Fudim, L., and Becker, M. (2023). Sex-Related Changes in the Clinical, Genetic, Electrophysiological, Connectivity, and Molecular Presentations of ASD: A Comparison between Human and Animal Models of ASD with Reference to Our Data. Int. J. Mol. Sci., 24. · DOI · Paper page
  141. American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders: DSM-5, American Psychiatric Association. · DOI · Paper page
  142. Rodier, 1996, Embryological origin for autism: Developmental anomalies of the cranial nerve motor nuclei, J. Comp. Neurol., 370, 247, 10.1002/(SICI)1096-9861(19960624)370:2<247::AID-CNE8>3.0.CO;2-2 · doi:10.1002/(sici)1096-9861(19960624)370:2<247::aid-cne8>3.0.co;2-2
  143. Bailey, 1996, Autism: Towards an Integration of Clinical, Genetic, Neuropsychological, and Neurobiological Perspectives, J. Child Psychol. Psychiatry, 37, 89, 10.1111/j.1469-7610.1996.tb01381.x · DOI · Paper page
  144. Kobayashi, 2019, Effects of rapamycin on social interaction deficits and gene expression in mice exposed to valproic acid in utero, Mol. Brain, 12, 3, 10.1186/s13041-018-0423-2 · DOI
  145. Zhao, 2019, Maternal valproic acid exposure leads to neurogenesis defects and autism-like behaviors in non-human primates, Transl. Psychiatry, 9, 267, 10.1038/s41398-019-0608-1 · DOI
  146. Weinstein-Fudim, L., Ergaz, Z., Turgeman, G., Yanai, J., Szyf, M., and Ornoy, A. (2019). Gender Related Changes in Gene Expression Induced by Valproic Acid in A Mouse Model of Autism and the Correction by S-adenosyl Methionine. Does It Explain the Gender Differences in Autistic Like Behavior?. Int. J. Mol. Sci., 20. · DOI · Paper page
  147. Ornoy, A., Weinstein-Fudim, L., and Becker, M. (2022). SAMe, Choline, and Valproic Acid as Possible Epigenetic Drugs: Their Effects in Pregnancy with a Special Emphasis on Animal Studies. Pharmaceuticals, 15. · DOI · Paper page
  148. Wang, 2013, Resting state EEG abnormalities in autism spectrum disorders, J. Neurodev. Disord., 5, 24, 10.1186/1866-1955-5-24 · DOI · Paper page
  149. Lenart, 2020, Altered expression of glutamatergic and GABAergic genes in the valproic acid-induced rat model of autism: A screening test, Toxicology, 440, 152500, 10.1016/j.tox.2020.152500 · DOI
  150. Feleke, 2022, Integrative genomics reveals pathogenic mediator of valproate-induced neurodevelopmental disability, Brain, 145, 3832, 10.1093/brain/awac296 · DOI
  151. Zhang, 2018, Transcriptional and splicing dysregulation in the prefrontal cortex in valproic acid rat model of autism, Reprod. Toxicol., 77, 53, 10.1016/j.reprotox.2018.01.008 · DOI
  152. Huang, 2016, Functional Genomic Analyses Identify Pathways Dysregulated in Animal Model of Autism, CNS Neurosci. Ther., 22, 845, 10.1111/cns.12582 · DOI
  153. Guerra, 2023, Fetal exposure to valproic acid dysregulates the expression of autism-linked genes in the developing cerebellum, Transl. Psychiatry, 13, 114, 10.1038/s41398-023-02391-9 · DOI
  154. Leto, 2016, Consensus Paper: Cerebellar Development, Cerebellum, 15, 789, 10.1007/s12311-015-0724-2 · DOI · Paper page
  155. Gottshall, 2016, Differential timing of granule cell production during cerebellum development underlies generation of the foliation pattern, Neural Dev., 11, 17, 10.1186/s13064-016-0072-z · DOI
  156. Sillitoe, 2007, Morphology, molecular codes, and circuitry produce the three-dimensional complexity of the cerebellum, Annu. Rev. Cell Dev. Biol., 23, 549, 10.1146/annurev.cellbio.23.090506.123237 · DOI · Paper page
  157. Weinstein-Fudim, L., Ergaz, Z., Szyf, M., and Ornoy, A. (2020). Prenatal S-Adenosine Methionine (SAMe) Induces Changes in Gene Expression in the Brain of Newborn Mice That Are Prevented by Co-Administration of Valproic Acid (VPA). Int. J. Mol. Sci., 21. · DOI
  158. Wegner, 1992, Alteration of embryonic folate metabolism by valproic acid during organogenesis: Implications for mechanism of teratogenesis, Neurology, 42, 17
  159. Reynolds, 2020, Antiepileptic drugs and folate revisited, Epilepsy Behav., 112, 107336, 10.1016/j.yebeh.2020.107336 · DOI
  160. Afman, 2006, Genetic variation in genes of folate metabolism and neural-tube defect risk, Proc. Nutr. Soc., 65, 204, 10.1079/PNS2006495 · DOI
  161. Hansen, 1995, Effect of supplemental folic acid on valproic acid-induced embryotoxicity and tissue zinc levels in vivo, Teratology, 52, 277, 10.1002/tera.1420520506 · DOI
  162. Semmler, 2017, Intrauterine valproate exposure is associated with alterations in hippocampal cell numbers and folate metabolism in a rat model of valproate teratogenicity, Seizure, 46, 7, 10.1016/j.seizure.2017.01.003 · DOI
  163. Semmler, 2012, The ratio of S-adenosylmethione and S-adenosyl-homocysteine is increased in the brains of newborn rats in a model of valproic acid teratogenicity, Toxicology, 293, 132, 10.1016/j.tox.2012.01.001 · doi:10.1016/j.tox.2012.01.001
  164. Bokor, S., Vass, R.A., Funke, S., Ertl, T., and Molnár, D. (2022). Epigenetic Effect of Maternal Methyl-Group Donor Intake on Offspring’s Health and Disease. Life, 12. · DOI
  165. Clare, 2019, One-Carbon Metabolism: Linking Nutritional Biochemistry to Epigenetic Programming of Long-Term Development, Annu. Rev. Anim. Biosci., 7, 263, 10.1146/annurev-animal-020518-115206 · DOI · Paper page
  166. Jacob, 2017, VPA Inhibits P19 Neural Differentiation through Redox Dysregulation and Oxidative Stress, Free Radic. Biol. Med., 112, 190, 10.1016/j.freeradbiomed.2017.10.298 · doi:10.1016/j.freeradbiomed.2017.10.298
  167. Lucas, S., and Hansen, J. (2018). Valproic acid inhibits superoxide dismutase activity in mouse P19 cells. Free Radic. Biol. Med., 128. · doi:10.1016/j.freeradbiomed.2018.10.289
  168. Piorczynski, 2018, The protective effects of Nrf2 against valproic acid in differentiating P19 cells, Free Radic. Biol. Med., 128, S118, 10.1016/j.freeradbiomed.2018.10.290 · doi:10.1016/j.freeradbiomed.2018.10.290
  169. Piorczynski, 2022, NRF2 activation protects against valproic acid-induced disruption of neurogenesis in P19 cells, Differentiation, 123, 18, 10.1016/j.diff.2021.12.002 · DOI
  170. Furugen, 2021, Effects of valproate, an HDAC inhibitor, on the expression of folate carriers and folate metabolism-related genes in the placenta of rats, Drug Metab. Pharmacokinet., 40, 100409, 10.1016/j.dmpk.2021.100409 · DOI
  171. Reynolds, 2020, Valproate and folate: Congenital and developmental risks, Epilepsy Behav., 108, 107068, 10.1016/j.yebeh.2020.107068 · DOI
  172. Copp, 2013, Neural tube defects: Recent advances, unsolved questions, and controversies, Lancet Neurol., 12, 799, 10.1016/S1474-4422(13)70110-8 · DOI · Paper page
  173. Heseker, 2008, Not all cases of neural-tube defect can be prevented by increasing the intake of folic acid, Br. J. Nutr., 102, 173, 10.1017/S0007114508149200 · DOI
  174. Lawrence, 2009, Examination of selected national policies towards mandatory folic acid fortification, Nutr. Rev., 67, S73, 10.1111/j.1753-4887.2009.00164.x · DOI
  175. Petersen, 2023, Periconceptional intakes of methyl donors and other micronutrients involved in one-carbon metabolism may further reduce the risk of neural tube defects in offspring: A United States population-based case-control study of women meeting the folic acid recommendations, Am. J. Clin. Nutr., 118, 720, 10.1016/j.ajcnut.2023.05.034 · DOI
  176. Shaw, 2004, Periconceptional dietary intake of choline and betaine and neural tube defects in offspring, Am. J. Epidemiol., 160, 102, 10.1093/aje/kwh187 · DOI · Paper page
  177. Williams, 2002, Prevalence of spina bifida and anencephaly during the transition to mandatory folic acid fortification in the United States, Teratology, 66, 33, 10.1002/tera.10060 · DOI · Paper page
  178. Lin, 2014, S-adenosylmethionine limitation induces p38 mitogen-activated protein kinase and triggers cell cycle arrest in G1, J. Cell Sci., 127, 50
  179. Akimova, 2017, Metabolite profiling of whole murine embryos reveals metabolic perturbations associated with maternal valproate-induced neural tube closure defects, Birth Defects Res., 109, 106, 10.1002/bdra.23583 · DOI
  180. D’Souza, S.W., and Glazier, J.D. (2022). Homocysteine Metabolism in Pregnancy and Developmental Impacts. Front. Cell Dev. Biol., 10. · DOI
  181. Zhu, 2021, Genetic Polymorphisms in Enzymes Involved in One-Carbon Metabolism and Anti-epileptic Drug Monotherapy on Homocysteine Metabolism in Patients with Epilepsy, Front. Neurol., 12, 683275, 10.3389/fneur.2021.683275 · DOI
  182. Zhao, 2006, Neural tube defects and maternal biomarkers of folate, homocysteine, and glutathione metabolism, Birth Defects Res. Part A Clin. Mol. Teratol., 76, 230, 10.1002/bdra.20240 · DOI
  183. 2002, Acute Valproate Administration Impairs Methionine Metabolism in Rats, J. Nutr., 132, 2737, 10.1093/jn/132.9.2737 · doi:10.1093/jn/132.9.2737
  184. Zhang, 2014, Histone deacetylase inhibitors and cell death, Cell. Mol. Life Sci., 71, 3885, 10.1007/s00018-014-1656-6 · DOI · Paper page
  185. Hsieh, 2013, Valproic acid substantially downregulated genes folr1, IGF2R, RGS2, COL6A3, EDNRB, KLF6, and pax-3, N-acetylcysteine alleviated most of the induced gene alterations in chicken embryo model, Rom. J. Morphol. Embryol., 54, 993
  186. Hsieh, 2012, Multiple point action mechanism of valproic acid-teratogenicity alleviated by folic acid, vitamin C, and N-acetylcysteine in chicken embryo model, Toxicology, 291, 32, 10.1016/j.tox.2011.10.015 · DOI
  187. Minucci, 2001, Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells, EMBO J., 20, 6969, 10.1093/emboj/20.24.6969 · DOI · Paper page
  188. Leung, 2023, Dysregulation of the chromatin environment leads to differential alternative splicing as a mechanism of disease in a human model of autism spectrum disorder, Hum. Mol. Genet., 32, 1634, 10.1093/hmg/ddad002 · DOI
  189. Danielsson, 2007, Embryonic cardiac arrhythmia and generation of reactive oxygen species: Common teratogenic mechanism for IKr blocking drugs, Reprod. Toxicol., 24, 42, 10.1016/j.reprotox.2007.04.005 · DOI
  190. Echefu, B.E., Bello, A., Musa, S.A., and Umana, U.E. (2022). Selenium Mitigates Prenatal Lead-Induced Toxicity on Cerebral Cortex of Wistar Rats Pups. Res. Sq., preprint. · doi:10.21203/rs.3.rs-1933946/v1
  191. Echefu, 2019, Selenium impact assessment on brains of prenatally lead exposed Wistar rats, IBRO Rep., 6, S338, 10.1016/j.ibror.2019.07.1043 · DOI
  192. Verrotti, 2008, Increased oxidative stress in epileptic children treated with valproic acid, Epilepsy Res., 78, 171, 10.1016/j.eplepsyres.2007.11.005 · DOI
  193. Ornoy, 2007, Embryonic oxidative stress as a mechanism of teratogenesis with special emphasis on diabetic embryopathy, Reprod. Toxicol., 24, 31, 10.1016/j.reprotox.2007.04.004 · DOI · Paper page
  194. Rahman, 2015, Astaxanthin improves behavioral disorder and oxidative stress in prenatal valproic acid-induced mice model of autism, Behav. Brain Res., 286, 112, 10.1016/j.bbr.2015.02.041 · DOI
  195. Finsterer, 2017, Toxicity of antiepileptic drugs to mitochondria, Handb. Exp. Pharmacol., 240, 473, 10.1007/164_2016_2 · doi:10.1007/164_2016_2
  196. Komulainen, 2015, Sodium valproate induces mitochondrial respiration dysfunction in HepG2 in vitro cell model, Toxicology, 331, 47, 10.1016/j.tox.2015.03.001 · DOI
  197. Karmirian, 2018, Deformation of Mitochondrial Cristae in Human Neural Progenitor Cells Exposed to Valproic Acid, Acad. Bras. Cienc., 90, 2223, 10.1590/0001-3765201820170762 · DOI
  198. Sendrowski, 2013, Ultrastructural study of hippocampal cortex neurons in an experimental model of valproate encephalopathy, Folia Histochem. Cytobiol., 51, 31, 10.5603/FHC.2013.005 · DOI
  199. Hroudova, 2010, Activities of respiratory chain complexes and citrate synthase influenced by pharmacologically different antidepressants and mood stabilizers, Neuro Endocrinol. Lett., 31, 336
  200. Kudin, A.P., Mawasi, H., Eisenkraft, A., Elger, C.E., Bialer, M., and Kunz, W.S. (2017). Mitochondrial Liver Toxicity of Valproic Acid and Its Acid Derivatives Is Related to Inhibition of α-Lipoamide Dehydrogenase. Int. J. Mol. Sci., 18. · DOI

200 of 230 shown

Cited by

See all 69

Metadata

Authors
Ornoy, A., Echefu, B., & Becker, M.
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2023-12-27
Volume
25
Issue
1
Pages
390
ISSN
1422-0067
Cited by
69
References
16
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Valproic Acid in Pregnancy Revisited: Neurobehavioral, Biochemical and Molecular Changes Affecting the Embryo and Fetus in Humans and in Animals: A Narrative Review. https://app.cochat.ai/papers/10.3390/ijms25010390
The paper
Ornoy, A., Echefu, B., & Becker, M. (2023). Valproic Acid in Pregnancy Revisited: Neurobehavioral, Biochemical and Molecular Changes Affecting the Embryo and Fetus in Humans and in Animals: A Narrative Review. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25010390

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.